Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort. (November 2017) - Bardia, Aditya; Cortés, Javier; Modi, Shanu; Oliveira, Mafalda; Campone, Mario; Ma, Brigette; Dirix, Luc; Weise, Amy; Kittaneh, Muaiad; Hewes, Becker; Wang, Yingbo; Stegert, Mario; et al.